개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학위논문
- 저자정보
- 지도교수
- 이혜윤
- 발행연도
- 2016
- 저작권
- 건양대학교 논문은 저작권에 의해 보호받습니다.
이용수0
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Myelosuppression, particularly neutropenia, is one of the most frequent and serious toxicity seen in patients with breast cancer undergoing systemic chemotherapy. However, the predictive factors for development of severe neutropenia in chemotherapy remain unknown. We therefore evaluated predictive factors for excessive myelosuppression.
We retrospectively analyzed 341 patients with breast cancer treated with chemotherapy from 2000 to 2012. Clinicopathological characteristics, number of using of granulocyte colony-stimulating factor (G-CSF), and pretreatment hematologic values were extracted from the electronic medical record system. Patients were sorted 2 groups by number of using G-CSF in each chemotherapeutic regimens; group 1 is more G-CSF (within high 20 percentile) and 2 less G-CSF using group (within lower 20 percentile).
Number of using G-CSF was ranged 0-83 (mean 10.76). 101 patients were in group 1 and 65 patients were in group 2. Mean of number of G-CSF using was 0.21 in group 1 and 28.02 in group 2. Pretreatment white blood cell, hemoglobin and platelet count were lower in group 2 than in group 1 (6.88 x 103/㎕ vs 5.97 x 103/㎕, 12.63g/dL vs 11.90g/dL and 275.95x104㎕ vs 227.37 x104㎕). There were no statistically differences in other clinicopathologic characteristics such as age, body mass index (BMI) or comorbidities, hormonal receptor, stage, and other pretreatment hematologic values.
Pretreatment white blood cell count, hemoglobin and platelet count can be used to identify patients at increased risk of significant myelosuppression undergoing chemotherapy with breast cancer. This information can be used to target high-risk patients for prophylactic treatment.
We retrospectively analyzed 341 patients with breast cancer treated with chemotherapy from 2000 to 2012. Clinicopathological characteristics, number of using of granulocyte colony-stimulating factor (G-CSF), and pretreatment hematologic values were extracted from the electronic medical record system. Patients were sorted 2 groups by number of using G-CSF in each chemotherapeutic regimens; group 1 is more G-CSF (within high 20 percentile) and 2 less G-CSF using group (within lower 20 percentile).
Number of using G-CSF was ranged 0-83 (mean 10.76). 101 patients were in group 1 and 65 patients were in group 2. Mean of number of G-CSF using was 0.21 in group 1 and 28.02 in group 2. Pretreatment white blood cell, hemoglobin and platelet count were lower in group 2 than in group 1 (6.88 x 103/㎕ vs 5.97 x 103/㎕, 12.63g/dL vs 11.90g/dL and 275.95x104㎕ vs 227.37 x104㎕). There were no statistically differences in other clinicopathologic characteristics such as age, body mass index (BMI) or comorbidities, hormonal receptor, stage, and other pretreatment hematologic values.
Pretreatment white blood cell count, hemoglobin and platelet count can be used to identify patients at increased risk of significant myelosuppression undergoing chemotherapy with breast cancer. This information can be used to target high-risk patients for prophylactic treatment.
목차
제1장 Introduction----------------------------------01제2장 Materials and Methods-----------------------021. Patients2 . Statistical analysis제3장 Results--------------------------------------04제4장 Discussion----------------------------------06제5장 Conclusion----------------------------------08참고문헌------------------------------------------09부록 및 초록-------------------------------------11감사의글------------------------------------------18
최근 본 자료
댓글(0)
0